• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Immunic Inc.

    12/8/25 11:45:04 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMUX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    IMMUNIC, INC.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    4525EP101

    (CUSIP Number)


    11/28/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    4525EP101


    1Names of Reporting Persons

    JANUS HENDERSON GROUP PLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    12,016,444.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    12,016,444.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,016,444.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IA, HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    IMMUNIC, INC.
    (b)Address of issuer's principal executive offices:

    1200 AVENUE OF THE AMERICAS, SUITE 200 NEW YORK, NY 10036
    Item 2. 
    (a)Name of person filing:

    Janus Henderson Group plc
    (b)Address or principal business office or, if none, residence:

    201 Bishopsgate EC2M 3AE, United Kingdom
    (c)Citizenship:

    Y9
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    4525EP101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    JHIUS may be deemed to be the beneficial owner of 12,016,444 shares, inclusive of certain pre-funded and/or common warrants (the Warrants). The Warrants are only exercisable within 60 days to the extent that, after giving effect to such exercise, the holders thereof and their affiliated persons would not beneficially own more than 9.99% of the outstanding common stock. Due to current common stock ownership levels, an additional 13,327,439 Series A and 13,327,439 Series B common warrants are therefore not reflected in the figures reported herein.
    (b)Percent of class:

    9.99  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    12016444

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    12016444

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    N/A
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries of Janus Henderson and are registered investment advisers furnishing investment advice to Managed Portfolios.
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    N/A
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    N/A

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    JANUS HENDERSON GROUP PLC
     
    Signature:Kristin Mariani
    Name/Title:Head of North America Compliance, CCO
    Date:12/08/2025
    Exhibit Information

    POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

    Get the next $IMUX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMUX

    DatePrice TargetRatingAnalyst
    11/7/2025$3.00Buy
    Roth Capital
    9/29/2025$13.00Buy
    Chardan Capital Markets
    3/25/2025Outperform
    William Blair
    11/25/2024$10.00Buy
    H.C. Wainwright
    9/9/2024$5.00Outperform
    Leerink Partners
    8/27/2024$6.00Buy
    B. Riley Securities
    10/21/2022$5.00Outperform → Mkt Perform
    SVB Leerink
    9/19/2022$26.00Buy
    H.C. Wainwright
    More analyst ratings

    $IMUX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: President and COO Tardio Jason bought $9,884 worth of shares (12,512 units at $0.79) (SEC Form 4)

    4/A - IMMUNIC, INC. (0001280776) (Issuer)

    6/20/25 5:16:19 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: CEO and Director Vitt Daniel bought $11,550 worth of shares (15,000 units at $0.77), increasing direct ownership by 107% to 29,000 units (SEC Form 4)

    4/A - IMMUNIC, INC. (0001280776) (Issuer)

    6/20/25 5:15:45 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman Nash Duane bought $16,694 worth of shares (20,000 units at $0.83), increasing direct ownership by 125% to 36,032 units (SEC Form 4)

    4 - IMMUNIC, INC. (0001280776) (Issuer)

    6/16/25 5:00:19 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

    NEW YORK, Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 4, 2025 at 9:35 am ET at the 8th Annual Evercore ISI Healthcare Conference, taking place December 2-4, 2025 in Coral Gables, FL. A webcast will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations. Dr. Vitt and Jason Tardio, President and Chief Operating Officer of Immunic, will also partici

    11/26/25 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic to Participate in Industry and Investor Conferences in November

    NEW YORK, Oct. 29, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in November: November 3-5: BIO-Europe. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, Hella Kohlhof, Ph.D., Chief Scientific Officer and Jessica Breu, Vice President Investor Relations and Communications, will participate in partnering activities at this conference in Vienna, Austria. To schedule a meeting, please use the BIO-Europe partneringONE portal or contact Jessica Breu at: jes

    10/29/25 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic to Participate in Scientific and Investor Conferences in October

    NEW YORK, Oct. 1, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in October: October 4-7: UEGW 2025 – United European Gastroenterology Week. Immunic's R&D team will attend this conference in Berlin, Germany. Data on IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), will be presented in an oral presentation, a publication, and an ePoster, all of which will be accessible on the "Events and Presentat

    10/1/25 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Immunic Inc.

    SCHEDULE 13G - IMMUNIC, INC. (0001280776) (Subject)

    12/8/25 11:45:04 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - IMMUNIC, INC. (0001280776) (Filer)

    11/13/25 7:26:52 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Immunic Inc.

    10-Q - IMMUNIC, INC. (0001280776) (Filer)

    11/13/25 7:17:05 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Whaley Glenn

    4 - IMMUNIC, INC. (0001280776) (Issuer)

    7/18/25 4:06:30 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Executive Chairman Nash Duane

    4 - IMMUNIC, INC. (0001280776) (Issuer)

    7/18/25 4:06:15 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO and Director Vitt Daniel

    4 - IMMUNIC, INC. (0001280776) (Issuer)

    7/18/25 4:05:56 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Immunic with a new price target

    Roth Capital initiated coverage of Immunic with a rating of Buy and set a new price target of $3.00

    11/7/25 8:30:20 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Immunic with a new price target

    Chardan Capital Markets initiated coverage of Immunic with a rating of Buy and set a new price target of $13.00

    9/29/25 9:57:47 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Immunic

    William Blair initiated coverage of Immunic with a rating of Outperform

    3/25/25 8:27:26 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Leadership Updates

    Live Leadership Updates

    View All

    Immunic Highlights 2024 Accomplishments and Upcoming Milestones

    – Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – – Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 – – Strengthened Management Team and Board of Directors with Key Hires – – Announced a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranche – NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered,

    1/7/25 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

    – Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevus® – NEW YORK, July 24, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Simona Skerjanec, M.Pharm, MBA, a thought-leader in brain health with decades of experience in drug development and commercialization, to its board of directors, effective July 22, 2024. Over a nea

    7/24/24 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic Appoints Jason Tardio as Chief Operating Officer and President

    – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President, Program Management & Clinical Development Operations, Promoted to Chief Development Officer – NEW YORK, July 9, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that seasoned biopharmaceutical executive, Jason Tardio, will be joining the company as Chief Operating Officer and President, effective July 12, 2024. In the newly created role, Mr. Tardio will lead in

    7/9/24 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Immunic Inc.

    SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)

    11/14/24 5:33:45 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immunic Inc.

    SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)

    11/14/24 12:30:35 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immunic Inc.

    SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)

    11/14/24 6:58:13 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Financials

    Live finance-specific insights

    View All

    Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

    – 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as well as All Subtypes – – NfL Effect in Non-Active Subpopulation Reinforces Vidofludimus Calcium's Neuroprotective Potential – – Brain Volume Data of the Full 467 CALLIPER Patient Cohort Expected in April 2025 – – Phase 3 ENSURE Program in Relapsing Multiple Sclerosis Ongoing – – Conference Call and Webcast to be Held Tomorrow, October 10, 2023 at 8:00 am ET – NEW YORK, Oct. 9, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chr

    10/9/23 4:01:00 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

    – Positive Effects Demonstrated Over Placebo in Four Key Dimensions of Celiac Disease Pathophysiology: Protection of Gut Architecture, Improvement of Patients' Symptoms, Biomarker Response, and Enhancement of Nutrient Absorption – – Corroborates Hypothesized Ability of IMU-856 to Renew Gut Wall and Restore Gut Health – – No Safety or Tolerability Issues Detected – – Conference Call and Webcast to be Held Today, May 4, 2023 at 8:00 am ET – NEW YORK, May 4, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive results fro

    5/4/23 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

    – 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of Vidofludimus Calcium Demonstrated Statistically Significant Rates of Clinical Remission (p=0.0358) and Endoscopic Healing (p=0.0259) at Week 50 – – To Focus Resources on High Performing Vidofludimus Calcium and IMU-856 Programs, Immunic Decided to Deprioritize Izumerogant (IMU-935) Program – – Conference Call and Webcast to be Held today, April 5, 2023 at 8:00 am ET – NEW YORK, April 5, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi

    4/5/23 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care